The VALOR Study – A Clinical Trial for People Living with SOD1-ALS

6 October 2020

Biogen is conducting a clinical trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS) carrying a SOD1 gene mutation.

Study Duration

  • 32-36 weeks, including:
  • 4-week screening
  • 24-week study treatment period
  • 4 to 8-week follow-up period

Investigational Drug

  • Tofersen (BIIB067), an antisense oligonucleotide (ASO)
  • Designed to reduce the amount of SOD1 protein in the body
  • Given intrathecally, through a lumbar puncture

Key Eligibility Criteria

  • 18 years of age or older
  • Have weakness caused by ALS
  • Agree to genetic testing for the SOD1 mutation

All Eligible Participants Will Receive At No Cost

  • Comprehensive study-related health evaluations and assessments, including genetic testing
  • Investigational drug or placebo
  • All study-related visits and care

Assistance with travel and accommodations, and reimbursement for study-related expenses may also be available. See if you may be eligible and view study locations.